REGENXBIO Inc. RB0.F Stock
REGENXBIO Inc. Price Chart
REGENXBIO Inc. RB0.F Financial and Trading Overview
REGENXBIO Inc. stock price | 11.5 EUR |
Previous Close | 18.1 EUR |
Open | 17.9 EUR |
Bid | 17.9 EUR x 50000 |
Ask | 18.1 EUR x 50000 |
Day's Range | 17.9 - 17.9 EUR |
52 Week Range | 16 - 34.4 EUR |
Volume | 90 EUR |
Avg. Volume | 1 EUR |
Market Cap | 778.04M EUR |
Beta (5Y Monthly) | 1.046126 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.85 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 65.13 EUR |
RB0.F Valuation Measures
Enterprise Value | 569.95M EUR |
Trailing P/E | N/A |
Forward P/E | -4.1244235 |
PEG Ratio (5 yr expected) | -4.88 |
Price/Sales (ttm) | 7.0961018 |
Price/Book (mrq) | 1.6727408 |
Enterprise Value/Revenue | 5.198 |
Enterprise Value/EBITDA | -2.275 |
Trading Information
REGENXBIO Inc. Stock Price History
Beta (5Y Monthly) | 1.046126 |
52-Week Change | -4.12% |
S&P500 52-Week Change | 20.43% |
52 Week High | 34.4 EUR |
52 Week Low | 16 EUR |
50-Day Moving Average | 17.52 EUR |
200-Day Moving Average | 21.29 EUR |
RB0.F Share Statistics
Avg. Volume (3 month) | 1 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 43.47M |
Float | 39.26M |
Short Ratio | N/A |
% Held by Insiders | 7.76% |
% Held by Institutions | 89.85% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -246.50% |
Operating Margin (ttm) | -241.69% |
Gross Margin | -160.65% |
EBITDA Margin | -228.47% |
Management Effectiveness
Return on Assets (ttm) | -18.68% |
Return on Equity (ttm) | -46.80% |
Income Statement
Revenue (ttm) | 109.64M EUR |
Revenue Per Share (ttm) | 2.53 EUR |
Quarterly Revenue Growth (yoy) | -13.90% |
Gross Profit (ttm) | -184274000 EUR |
EBITDA | -250510000 EUR |
Net Income Avi to Common (ttm) | -270273984 EUR |
Diluted EPS (ttm) | -5.76 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 331.82M EUR |
Total Cash Per Share (mrq) | 7.63 EUR |
Total Debt (mrq) | 93.3M EUR |
Total Debt/Equity (mrq) | 20.06 EUR |
Current Ratio (mrq) | 3.465 |
Book Value Per Share (mrq) | 10.701 |
Cash Flow Statement
Operating Cash Flow (ttm) | -232495008 EUR |
Levered Free Cash Flow (ttm) | -169971120 EUR |
Profile of REGENXBIO Inc.
Country | Germany |
State | MD |
City | Rockville |
Address | 9804 Medical Center Drive |
ZIP | 20850 |
Phone | 240 552 8181 |
Website | https://www.regenxbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 401 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. In addition, it also develops RGX-121 for the treatment of mucopolysaccharidosis type II and is in Phase III clinical trial; RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. Further, the company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Q&A For REGENXBIO Inc. Stock
What is a current RB0.F stock price?
REGENXBIO Inc. RB0.F stock price today per share is 11.5 EUR.
How to purchase REGENXBIO Inc. stock?
You can buy RB0.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for REGENXBIO Inc.?
The stock symbol or ticker of REGENXBIO Inc. is RB0.F.
Which industry does the REGENXBIO Inc. company belong to?
The REGENXBIO Inc. industry is Biotechnology.
How many shares does REGENXBIO Inc. have in circulation?
The max supply of REGENXBIO Inc. shares is 49.26M.
What is REGENXBIO Inc. Price to Earnings Ratio (PE Ratio)?
REGENXBIO Inc. PE Ratio is now.
What was REGENXBIO Inc. earnings per share over the trailing 12 months (TTM)?
REGENXBIO Inc. EPS is -5.85 EUR over the trailing 12 months.
Which sector does the REGENXBIO Inc. company belong to?
The REGENXBIO Inc. sector is Healthcare.